EA201391689A1 - Система доставки лекарственного средства - Google Patents

Система доставки лекарственного средства

Info

Publication number
EA201391689A1
EA201391689A1 EA201391689A EA201391689A EA201391689A1 EA 201391689 A1 EA201391689 A1 EA 201391689A1 EA 201391689 A EA201391689 A EA 201391689A EA 201391689 A EA201391689 A EA 201391689A EA 201391689 A1 EA201391689 A1 EA 201391689A1
Authority
EA
Eurasian Patent Office
Prior art keywords
present
immediate
controlled
active ingredient
delivery system
Prior art date
Application number
EA201391689A
Other languages
English (en)
Other versions
EA034288B1 (ru
Inventor
Йоханнес Мартинус Мария Блумерс
Анко Корнелус Эйссенс
Хендерик Виллем Фрейлинк
Леонардус Герардус Йозеф Де Леде
Original Assignee
Эмоушнл Брэйн Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмоушнл Брэйн Б.В. filed Critical Эмоушнл Брэйн Б.В.
Publication of EA201391689A1 publication Critical patent/EA201391689A1/ru
Publication of EA034288B1 publication Critical patent/EA034288B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к регулируемой во времени, с немедленным высвобождением системе доставки лекарственного средства для перорального введения первого активного ингредиента нуждающемуся в этом пациенту. Настоящее изобретение дополнительно относится к устройству для доставки двойного лекарственного средства, включающему регулируемую во времени, с немедленным высвобождением систему доставки лекарственного средства согласно настоящему изобретению, дополнительно включающему вторую оболочку, включающую второй активный ингредиент.
EA201391689A 2011-05-13 2012-05-14 Система доставки лекарственного средства EA034288B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11166091 2011-05-13
EP11181165 2011-09-13
EP11183732 2011-10-03
PCT/NL2012/050336 WO2012158030A2 (en) 2011-05-13 2012-05-14 Drug delivery system

Publications (2)

Publication Number Publication Date
EA201391689A1 true EA201391689A1 (ru) 2014-05-30
EA034288B1 EA034288B1 (ru) 2020-01-24

Family

ID=46197660

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391689A EA034288B1 (ru) 2011-05-13 2012-05-14 Система доставки лекарственного средства

Country Status (14)

Country Link
US (4) US9763884B2 (ru)
EP (1) EP2709597A2 (ru)
JP (1) JP6121990B2 (ru)
KR (2) KR102158948B1 (ru)
CN (2) CN109908099B (ru)
AU (1) AU2012256501B2 (ru)
BR (1) BR112013029199B1 (ru)
CA (1) CA2835845C (ru)
EA (1) EA034288B1 (ru)
IL (1) IL229425B (ru)
MX (1) MX353623B (ru)
SG (2) SG194943A1 (ru)
WO (1) WO2012158030A2 (ru)
ZA (1) ZA201309156B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160095818A1 (en) * 2013-06-03 2016-04-07 Mcneil Ab Solid pharmaceutical dosage form for release of at least one active pharmaceutical ingredient in the oral cavity
US20160279146A1 (en) 2013-11-11 2016-09-29 Limoxifen B.V. Methods and pharmaceutical formulations for treatment of selective estrogen-receptor modulator-induced adverse drug reactions
EP3248592A1 (en) * 2016-05-25 2017-11-29 EB IP Hybritabs B.V. Process for the preparation of drug delivery systems having a testosterone compound present in an outer layer or part, as well as such drug delivery systems
EP3731821A1 (en) 2017-12-29 2020-11-04 Laxxon Medical AG Drug delivery system
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
KR102084602B1 (ko) * 2018-11-08 2020-03-04 주식회사 서흥 발포성 및 안정성이 향상된 구강 세정용 발포정

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
US5120720A (en) * 1990-09-20 1992-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
AU3949093A (en) * 1992-03-31 1993-11-08 Benzon Pharma A/S A pharmaceutical formulation
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
EP0758653A4 (en) 1995-03-01 1998-06-10 Kyowa Hakko Kogyo Kk IMIDAZOQUINAZOLINE DERIVATIVES
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP3134187B2 (ja) * 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
AU5310898A (en) 1996-12-20 1998-07-17 Dumex-Alpharma A/S Release-controlled coated tablets
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
JP2001519379A (ja) 1997-10-09 2001-10-23 ペリオ、プロダクツ、リミテッド 遅延性総放出胃腸薬物送達システム
DE69923200T2 (de) * 1998-10-01 2005-12-22 Novartis Ag Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
US6977083B1 (en) * 1998-10-02 2005-12-20 Jenapharm Gmbh & Co. Kg Bioadhesive tablet containing testosterone/testosterone ester mixtures and method for producing a predetermined testosterone time-release profile with same
UA67802C2 (ru) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ ИНГИБИТОРА цГМФ ФДЭ-5 (ВАРИАНТЫ), СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СПОСОБ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
SE9902386D0 (sv) 1999-06-22 1999-06-22 Astra Ab New formulation
US20030027804A1 (en) 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
WO2003033025A2 (en) * 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
CN1946376A (zh) * 2004-03-25 2007-04-11 布里斯托尔-迈尔斯·斯奎布公司 包衣片剂组合物及其制法
CN102512681A (zh) 2004-05-11 2012-06-27 情感智能有限责任公司 药物制剂及其在治疗女性性功能障碍中的应用
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
WO2006123364A2 (en) * 2005-03-14 2006-11-23 Sun Pharmaceutical Industries Limited Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative
FR2883179B1 (fr) * 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
EP1898888A2 (en) * 2005-06-29 2008-03-19 Wyeth a Corporation of the State of Delaware Formulations of conjugated estrogens and bazedoxifene
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN100551373C (zh) 2005-12-01 2009-10-21 北京华素制药股份有限公司 盐酸丁螺环酮缓/控释微丸
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
GB0606562D0 (en) 2006-03-31 2006-05-10 Novartis Ag Organic compounds
TW200806282A (en) 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
ES2626632T3 (es) 2006-05-09 2017-07-25 Mallinckrodt Llc Formas de dosificación sólidas de liberación modificada de orden cero
MX2009000320A (es) * 2006-07-11 2009-06-05 Mutual Pharmaceutical Co Formulaciones de liberacion controlada.
EA200900264A1 (ru) * 2006-08-14 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Композиции флибансерина и способ их приготовления
EP1925307A1 (en) * 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
WO2009098697A1 (en) 2008-02-08 2009-08-13 Dexxon Ltd. Modafinil and sildenafil dosage forms
JP5777273B2 (ja) 2008-07-10 2015-09-09 大正製薬株式会社 不快な呈味を有する薬物を含有する製剤粒子
EP2478919A4 (en) 2009-09-15 2014-04-30 Team Academy Of Pharmaceutical Science CONTROLLED RELEASE TABLET INCORPORATING AN OSMOTIC PUMP AND METHOD FOR PREPARING THE SAME

Also Published As

Publication number Publication date
MX353623B (es) 2018-01-22
US20170354605A1 (en) 2017-12-14
NZ618535A (en) 2016-03-31
CN103648487A (zh) 2014-03-19
EA034288B1 (ru) 2020-01-24
JP2014513685A (ja) 2014-06-05
BR112013029199A8 (pt) 2018-02-06
BR112013029199A2 (pt) 2017-02-14
MX2013013204A (es) 2014-06-06
US10966933B2 (en) 2021-04-06
WO2012158030A2 (en) 2012-11-22
KR102158948B1 (ko) 2020-09-24
CN109908099A (zh) 2019-06-21
SG194943A1 (en) 2013-12-30
AU2012256501B2 (en) 2017-04-06
IL229425A0 (en) 2014-01-30
CA2835845C (en) 2020-07-28
AU2012256501A1 (en) 2013-12-19
NZ717187A (en) 2017-08-25
EP2709597A2 (en) 2014-03-26
WO2012158030A3 (en) 2013-04-18
BR112013029199B1 (pt) 2022-02-08
KR20190083369A (ko) 2019-07-11
CA2835845A1 (en) 2012-11-22
CN103648487B (zh) 2019-04-19
IL229425B (en) 2020-05-31
US20150056277A1 (en) 2015-02-26
KR20140048882A (ko) 2014-04-24
US20240165032A1 (en) 2024-05-23
SG10201606751XA (en) 2016-10-28
JP6121990B2 (ja) 2017-04-26
ZA201309156B (en) 2015-02-25
CN109908099B (zh) 2021-10-29
US9763884B2 (en) 2017-09-19
US20210290551A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
EA201391689A1 (ru) Система доставки лекарственного средства
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2012109022A3 (en) Medical fluid delivery device programming
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
WO2011157416A3 (de) Transdermale verabreichung von memantin
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
MY163809A (en) Transdermal drug delivery system containing donepezil
PH12014502107B1 (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
PH12014501408A1 (en) Immediate release multi unit pellet system
CR20140358A (es) Sistema para la administración de fármacos
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
MX2015007731A (es) Formulacion farmaceutica que comprende ciclesonida.
MX2016000103A (es) Dispositivo de administracion de farmaco oral y metodos de uso del mismo.
EA201992463A1 (ru) Система доставки лекарственного средства
PH12014501822A1 (en) Oral formulation comprising lansoprazole and the preparation method thereof
UA113061C2 (xx) Система доставки лікарського засобу
MX2020006886A (es) Sistema para suministro de medicamento.
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM